Supplementary Material for: Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer

<b><i>Objective:</i></b> Gemcitabine-based chemotherapy is regarded as the standard treatment for biliary tract cancer (BTC). Potential biomarkers for gemcitabine response include the activities of cytidine deaminase (CDA), human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (DCK), and ribonucleotide reductase M1 (RRM1). Here, we investigated whether single nucleotide polymorphisms (SNPs) in their encoding genes were associated with the efficacy of gemcitabine chemotherapy in treating BTC. <b><i>Methods:</i></b> We retrospectively evaluated 11 SNPs in the <i>CDA, hENT1, DCK, </i>human concentrative nucleoside transporter 3 <i>(hCNT3)</i>, and<i> RRM1</i> genes in 80 patients with unresectable, metastatic, or recurrent BTC who were treated with gemcitabine plus cisplatin. <b><i>Results:</i></b> After the results were adjusted for clinical predictors, the variant allele of rs1048977 in the <i>CDA </i>gene was associated with tumor response in a dominant model (OR, 0.23; 95% CI, 0.06-0.93; p = 0.039). No significant association was detected between the 11 SNPs and grade 3/4 toxicity. <b><i>Conclusions:</i></b> Our findings suggest that the polymorphism of <i>CDA</i> may be a potential predictive marker for the efficacy of gemcitabine-based chemotherapy in patients with BTC.